Crism Therapeutics Corporation Director Dealing

RNS Number : 9176Q

Crism Therapeutics Corporation

03 June 2024

 

3 June 2024

 

CRISM Therapeutics Corporation

(AIM:CRTX)

 

Director Dealing

 

CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 25,000 ordinary shares of the Company at a price of 9.265 pence per share.

 

Following this purchase, Mr Beaney holds 25,000 ordinary shares, which represents approximately 0.08% of the Company's total issued share capital of 32,678,312.

 

 

Enquiries:

 

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Buchanan
Andrew Webb, CEO Chris McConville, CSO	Richard Morrison Adam Cowl	Mark Court [e-mail] Jamie Hooper [e-mail]
via Buchanan	[phone]	[phone]

 

 

 

Dealings by Persons Discharging Managerial Responsibilities

 

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Gerald Beaney
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	CRISM Therapeutics Corporation
b)	LEI	213800XFW6MKVCHHPW88
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares with no par value
	Identification code	ISIN: VGG042401262
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)		Director/PDMR Price Volume Gerald Beaney 9.265 25,000
d)	Aggregated information
	- Aggregated volume	25,000
	- Price	£2,316.25
e)	Date of the transaction	3 June 2024
f)	Place of the transaction	Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

DSHFLFFSRSIVIIS